Glucaric acid

Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Glucaric acid?

Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Glucaric acid

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Brain Ischemia D002545 89 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Hyperlipidemias D006949 73 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Parkinson Disease D010300 53 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Precancerous Conditions D011230 48 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 50 100 | Total 85

PubChem Associated disorders and diseases

What pathways are associated with Glucaric acid

Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Glucaric acid?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Glucaric acid?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Glucaric acid?

There are no associated biomedical information in the current reference collection.

What genes are associated with Glucaric acid?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Glucaric acid?

Knock-out

Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Glucaric acid

Download all related citations
Per page 10 20 50 100 | Total 1061
Authors Title Published Journal PubMed Link
Ibrahim HN et al. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. 2009 Clin J Am Soc Nephrol pmid:19211669
Haddad A et al. Use of iron sucrose in dialysis patients sensitive to iron dextran. 2009 Saudi J Kidney Dis Transpl pmid:19237805
Pollak VE et al. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. 2009 BMC Nephrol pmid:19245700
Torres-Corzo JG et al. Comparison of cerebrospinal fluid obtained by ventricular endoscopy and by lumbar puncture in patients with hydrocephalus secondary to neurocysticercosis. 2009 Surg Neurol pmid:19249584
Clark SF Iron deficiency anemia: diagnosis and management. 2009 Curr. Opin. Gastroenterol. pmid:19262200
Muñoz M et al. [Usefulness of the administration of intravenous iron sucrose for the correction of preoperative anemia in major surgery patients]. 2009 Med Clin (Barc) pmid:19264195
Vanin S et al. Seasonal variation of trehalose and glycerol concentrations in winter snow-active insects. 2008 Nov-Dec Cryo Letters pmid:19280052
Breborowicz A et al. Intravenous iron sucrose changes the intraperitoneal homeostasis. 2009 Blood Purif. pmid:19325240
Lindgren S et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. 2009 Scand. J. Gastroenterol. pmid:19330567
Kim YH et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. 2009 Acta Haematol. pmid:19332985
Zanor MI et al. Metabolic characterization of loci affecting sensory attributes in tomato allows an assessment of the influence of the levels of primary metabolites and volatile organic contents. 2009 J. Exp. Bot. pmid:19346240
Gorder V et al. Treatment of restless legs syndrome with iron infusion therapy. 2009 JAAPA pmid:19354112
Nakamura Y et al. Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. 2008 Drug Metab Lett pmid:19356106
De Saint-Hubert M et al. Molecular imaging of cell death. 2009 Methods pmid:19362149
pmid:19379368
Bencaiova G et al. Iron prophylaxis in pregnancy: intravenous route versus oral route. 2009 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:19406557
pmid:19432851
Luo Z et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. 2009 Endocrine pmid:19440859
pmid:19481054
Grote L et al. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. 2009 Mov. Disord. pmid:19489063
Kulnigg S et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. 2009 Am. J. Gastroenterol. pmid:19491860
Asma S et al. Safety, therapeutic effectiveness, and cost of parenteral iron therapy. 2009 Int. J. Hematol. pmid:19495930
García-Erce JA et al. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. 2009 Vox Sang. pmid:19497085
Nguyen TV Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. 2009 Am J Health Syst Pharm pmid:19498125
Fontés G et al. Involvement of Per-Arnt-Sim Kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. 2009 Diabetes pmid:19502418
Krafft A et al. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone. 2009 Fetal. Diagn. Ther. pmid:19506383
Toblli JE et al. Differences between original intravenous iron sucrose and iron sucrose similar preparations. 2009 Arzneimittelforschung pmid:19517894
Shimizu Y et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. 2009 Bone pmid:19555782
Li H and Wang SX [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study]. 2009 Zhonghua Yi Xue Za Zhi pmid:19567093
Yi CX et al. A major role for perifornical orexin neurons in the control of glucose metabolism in rats. 2009 Diabetes pmid:19592616
Barraclough KA et al. Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). 2009 BMC Nephrol pmid:19635169
Dueber JE et al. Synthetic protein scaffolds provide modular control over metabolic flux. 2009 Nat. Biotechnol. pmid:19648908
Dong T and Schellhorn HE Global effect of RpoS on gene expression in pathogenic Escherichia coli O157:H7 strain EDL933. 2009 BMC Genomics pmid:19650909
DeLisa MP and Conrado RJ Synthetic metabolic pipelines. 2009 Nat. Biotechnol. pmid:19668178
pmid:19717754
Edwards TJ et al. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. 2009 Br J Surg pmid:19731228
Gehret TC et al. Convenient large-scale synthesis of D-glucaro-1,4:6,3-dilactone. 2009 J. Org. Chem. pmid:19777999
Muñoz M et al. Intravenous iron in inflammatory bowel disease. 2009 World J. Gastroenterol. pmid:19787830
Smith TG et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. 2009 JAMA pmid:19809026
Comín-Colet J et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. 2009 J. Card. Fail. pmid:19879457
Ball LM et al. Formation of mutagenic urinary metabolites from 1-nitropyrene in germ-free and conventional rats: role of the gut flora. 1991 Carcinogenesis pmid:1988167
McMahon LP et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. 2010 Nephrol. Dial. Transplant. pmid:19906658
Orlandi C et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. 1991 J. Nucl. Med. pmid:1992031
Morimoto S et al. Significance of urinary glucaric acid measurement and its application to paclitaxel therapy. 2009 Gan To Kagaku Ryoho pmid:19920388
Gambini JP et al. Evaluation of patients with head and neck cancer by means of 99mTc-glucarate. 2009 J Nucl Med Technol pmid:19949020
Stancu S et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? 2010 Clin J Am Soc Nephrol pmid:20019121
Sienkiewicz-Porzucek A et al. Mild reductions in mitochondrial NAD-dependent isocitrate dehydrogenase activity result in altered nitrate assimilation and pigmentation but do not impact growth. 2010 Mol Plant pmid:20035036
Fior S and Gerola PD Impact of ubiquitous inhibitors on the GUS gene reporter system: evidence from the model plants Arabidopsis, tobacco and rice and correction methods for quantitative assays of transgenic and endogenous GUS. 2009 Plant Methods pmid:20042078
Ginsberg G and Rice DC Does rapid metabolism ensure negligible risk from bisphenol A? 2009 Environ. Health Perspect. pmid:20049111
Dangsuwan P and Manchana T Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. 2010 Gynecol. Oncol. pmid:20051288